By Amina Niasse NEW YORK, Nov 14 (Reuters) – CVS Health said employers and other health plan sponsors could break even on GLP-1 drugs if they are priced below $350 per month as reduced use of medical
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)